Novo Nordisk US Bio Production Inc. – FDA 483, Feb 14, 2020
An FDA inspection of Novo Nordisk US Bio Production Inc. in West Lebanon, NH, a drug substance manufacturing facility, revealed significant deficiencies in quality control. Observations included inadequate laboratory controls for microbial detection, insufficient in-process hold time studies, and scientifically unsound corrective actions. Additionally, the firm failed to follow written procedures for contaminant identification and had inadequate written procedures for OOS investigations and employee training.
ID · f06cacda-b4ef-4e21-ab5f-5da19faa4684
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.